Project Grant R43AI197768
Award Date 8/14/26
Completion Date 7/31/28
Dollars Obligated $307K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Berkeley, CA 94702, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Celdara Medical, LLC $320,863 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop precision chimeric antigen receptor (CAR) natural killer cell therapy targeting VK4-1-overexpressing autoreactive B cells in systemic lupus erythematosus. The Phase I SBIR project seeks to selectively remove disease-causing B cells while preserving non-pathogenic immune function, using humanized...
- This $600,000 project grant from the National Institute of Allergy and Infectious Diseases will support General Nanotherapeutics LLC's development of nanoimmunotherapy for chronic immune-mediated diseases. The company will leverage nanoparticles to target and expand immunoregulatory cells ex vivo and assess their ability to suppress effector immune responses and induce remission in vivo, including in a lupus model. This proof-of-concept work aligns with the Allergy and Infectious Diseases...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, awarded $306,810 to Capture Bioscience Inc. on July 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for development and validation of a high-throughput autoimmune antibody detection platform. Capture Bioscience will adapt its Beads by Time-of-Flight (B-TOF) technology to create a comprehensive autoimmunity panel capable of simultaneously...
- The National Institute of Allergy and Infectious Diseases awarded La Jolla Institute for Immunology $929,095 on June 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize immune cell populations in lymphoid tissue from systemic lupus erythematosus patients and healthy controls using minimally invasive nasal swab sampling combined with flow cytometry and transcriptomic profiling. The research addresses gaps in understanding tissue-specific immune...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $748,333 on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to examine interferon-dependent and interferon-independent pathways in systemic lupus erythematosus. The research will classify SLE patients into mechanistically distinct disease subsets based on interferon expression patterns and identify factors that produce an interferon signature independent of...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services National Institutes of Health, awarded The Leland Stanford Junior University $127,926 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize autoreactive B cells and their roles in systemic lupus erythematosus (SLE) pathogenesis using immune organoids. The research investigates how autoreactive B cells transition from a...
- The National Institute of Allergy and Infectious Diseases awarded Abterra Biosciences, Inc. $306,555 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a serum antibody repertoire analysis platform for diagnosing systemic lupus erythematosus. Abterra will develop CDR3-SEQ, a novel technology platform that profiles over 1,000 antibody sequences from serum by analyzing the complementarity determining region 3 (CDRH3), the key domain for...
- The National Institute of Allergy and Infectious Diseases awarded The Feinstein Institutes for Medical Research $209,375 on April 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of autophagy in B cell tolerance and its relationship to systemic lupus erythematosus. The research examines how autophagy defects contribute to loss of B cell tolerance in autoimmune disease, specifically exploring crosstalk between autophagy pathways and...
- The National Institute of Allergy and Infectious Diseases awarded The Wistar Institute of Anatomy and Biology $281,620 on July 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel anti-LAG3 nanobodies for inflammation regulation and cancer immunotherapy. The project addresses T cell exhaustion in tumor-infiltrating lymphocytes by targeting lymphocyte activation gene 3 (LAG3), an inhibitory co-receptor that facilitates exhaustion of cytotoxic T cells...
- The National Institute of Allergy and Infectious Diseases awarded $499,175 to the University of Pittsburgh on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct genetic and functional dissection of tissue-infiltrating and age-associated B cells in murine lupus models. The research aims to identify and characterize pathogenic B cell subsets in systemic lupus erythematosus (SLE), with particular focus on age-associated B cells (ABCs) that...